TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
B: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
C: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: AMR101 (ethyl icosapentate) - 2 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 2 g/day | Arm Label: AMR101 (ethyl icosapentate) - 4 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 4 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 2 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 2 g/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: General Anesthesia; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Conscious Sedation with Remifentanil; Type: EXPERIMENTAL; Interventions: Drug: Conscious Sedation with Remifentanil | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): General Anesthesia | Intervention Type: DRUG; Name: Conscious Sedation with Remifentanil; Assigned to Arm(s): Conscious Sedation with Remifentanil
B: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
C: Arm Label: general anesthesia; Type: EXPERIMENTAL; Interventions: Drug: Etomidate, Drug: Succinylcholine, Drug: Propofol, Drug: Remifentanil | Arm Label: sedation; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil, Drug: Lidocaine | Intervention Type: DRUG; Name: Etomidate; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Succinylcholine; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): general anesthesia, sedation | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): sedation
D: Arm Label: Local anesthesia/conscious sedation; Type: OTHER; Interventions: Procedure: Local anesthesia/concious sedation, Procedure: Spontaneous breath | Arm Label: General anesthesia; Type: OTHER; Interventions: Procedure: General anesthesia, Procedure: Controlled ventilation | Intervention Type: PROCEDURE; Name: General anesthesia; Assigned to Arm(s): General anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia/concious sedation; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Spontaneous breath; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Controlled ventilation; Assigned to Arm(s): General anesthesia

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2
D: Arm Label: Merci Retriever; Type: ACTIVE_COMPARATOR; Interventions: Device: Mechanical Thrombectomy | Arm Label: Trevo Stentriever; Type: EXPERIMENTAL; Interventions: Device: Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Mechanical Thrombectomy; Assigned to Arm(s): Merci Retriever, Trevo Stentriever

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eicosapentaenoic acid ethyl ester | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester; Assigned to Arm(s): A
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intra-arterial Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Intra-arterial Therapy | Intervention Type: PROCEDURE; Name: Intra-arterial Therapy; Assigned to Arm(s): Intra-arterial Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Study
Brief Summary: Postoperative pancreatic fistula (POPF) remains a challenge even at specialized centers, and also affect significantly the surgical outcomes . The incidence of POPF after pancreaticoduodenectomy among different studies, ranging from 5 to 30%.Morbidity and mortality after pancreaticoduodenectomy are usually related to surgical management of the pancreatic stump. The safe pancreatic reconstruction after pancreaticoduodenectomy continues to be a challenge at high volume centers. The variety of reconstruction is a reflection of the lack of ideal one.Duct to mucosa and invagination are two classic PJ techniques. Many studies compared both techniques, but their surgical outcomes still unclear.The aim of the study was to assess the effectiveness and surgical outcomes of both techniques of PJ after pancreaticoduodenectomy.


Options:
A: Arm Label: horizontal mattress; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with horizontal mattress suture | Arm Label: interrupted suture; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with interrupted suture | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with horizontal mattress suture; Assigned to Arm(s): horizontal mattress | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with interrupted suture; Assigned to Arm(s): interrupted suture
B: Arm Label: Duct to mucosa PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Duct to mucosa PJ group | Arm Label: Invagination PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination PJ group | Intervention Type: PROCEDURE; Name: Duct to mucosa PJ group; Assigned to Arm(s): Duct to mucosa PJ group | Intervention Type: PROCEDURE; Name: Invagination PJ group; Assigned to Arm(s): Invagination PJ group
C: Arm Label: Mucosa-to-jejunal mucosa technique of pancreaticojejunosto; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): Mucosa-to-jejunal mucosa technique of pancreaticojejunosto
D: Arm Label: Nonstented stump-closed anastomosis; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Arm Label: Duct-to-mucosa anastomosis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): Duct-to-mucosa anastomosis, Nonstented stump-closed anastomosis

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Dietary Protein From Meat vs. Dairy on Infant Growth, Body Composition and Gut Health
Brief Summary: Current research shows that dairy protein accelerates infant weight gain, which is a risk factor for later on obesity and metabolic syndrome. However, dietary protein from other sources haven't been studied yet. This longitudinal study will compare two complementary feeding regimens with dietary protein mainly from 1) meat; 2) dairy on infant growth, body composition and gut microbiome from 5 to 12 months of age in formula fed infants. Healthy infants at approximately 5 months of age will be randomized to either a meat protein, or a dairy protein group with complementary protein mainly from meat or dairy. Infants will consume one of these diets for 7 months (6-12 months of age) and infant growth, body composition, growth biomarkers and gut microbiome will be measured to compare between groups and over time.


Options:
A: Arm Label: Meat; Type: ACTIVE_COMPARATOR; Interventions: Other: Meat | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Arm Label: Fortified rice cereal; Type: ACTIVE_COMPARATOR; Interventions: Other: fortified rice cereal | Intervention Type: OTHER; Name: Meat; Assigned to Arm(s): Meat | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: fortified rice cereal; Assigned to Arm(s): Fortified rice cereal
B: Arm Label: Traditional Diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cereal; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Caterpillar Cereal | Intervention Type: DIETARY_SUPPLEMENT; Name: Caterpillar Cereal; Assigned to Arm(s): Cereal
C: Arm Label: meat group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with meat | Arm Label: dairy group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with dairy | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with meat; Assigned to Arm(s): meat group | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with dairy; Assigned to Arm(s): dairy group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Brief Summary: The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and tolerability in the study population.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 2.5 µg | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 5.0 µg | Intervention Type: DRUG; Name: Nalfurafine HCl 2.5 µg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nalfurafine HCl 5.0 µg; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: nalbuphine HCl ER 60mg; Type: EXPERIMENTAL; Interventions: Drug: nalbuphine HCl ER tablets 60 mg BID | Arm Label: nalbuphine HCl ER 120mg; Type: EXPERIMENTAL; Interventions: Drug: nalbuphine HCl ER tablets 120mg BID | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets BID | Intervention Type: DRUG; Name: nalbuphine HCl ER tablets 60 mg BID; Assigned to Arm(s): nalbuphine HCl ER 60mg | Intervention Type: DRUG; Name: nalbuphine HCl ER tablets 120mg BID; Assigned to Arm(s): nalbuphine HCl ER 120mg | Intervention Type: DRUG; Name: Placebo tablets BID; Assigned to Arm(s): Sugar pill
C: Arm Label: Wheat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Wheat | Arm Label: Fumaria; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaria | Intervention Type: DRUG; Name: Wheat; Assigned to Arm(s): Wheat | Intervention Type: DRUG; Name: Fumaria; Assigned to Arm(s): Fumaria
D: Arm Label: hemodialysis+hemoperfusion (HA330); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA330) | Arm Label: hemodialysis+hemoperfusion (HA130); Type: EXPERIMENTAL; Interventions: Other: hemodialysis only, Other: hemodialysis plus hemoperfusion(HA130) | Arm Label: hemodialysis only; Type: ACTIVE_COMPARATOR; Interventions: Other: hemodialysis only | Intervention Type: OTHER; Name: hemodialysis only; Assigned to Arm(s): hemodialysis only, hemodialysis+hemoperfusion (HA130), hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA330); Assigned to Arm(s): hemodialysis+hemoperfusion (HA330) | Intervention Type: OTHER; Name: hemodialysis plus hemoperfusion(HA130); Assigned to Arm(s): hemodialysis+hemoperfusion (HA130)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province
Brief Summary: This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of Plasmodium spp. infection and disease in children aged 5-10 years in a treatment to re-infection study design. In order the clear liver-stage/blood-stages G6PD-normal children were randomised to receive Chloroquine (3 days, standard dose) and Coartem (3 days, standard dose) plus either i) primaquine (20 days, 0.5mg/kg) or ii) placebo (20days). These drugs were administered over a period of 4 weeks.

In addition to this epidemiological data, the study will assess the natural acquisition of cellular and humoral immune responses to P. falciparum and P. vivax, thus assisting in the determination of correlates of clinical immunity to P. falciparum and P. vivax in PNG children aged 5-10 years.

These data will not only be essential for development of future vaccines against P. vivax and P falciparum but provide invaluable insight into the contribution of long-lasting liver-stages to the force of infection with P. vivax that will contribute towards designing more rational approaches to the treatment of P. vivax both in the context of case management and future attempts at elimination.


Options:
A: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A
B: Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Arm Label: Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine/Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine/Primaquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine | Intervention Type: DRUG; Name: Chloroquine/Primaquine; Assigned to Arm(s): Chloroquine/Primaquine
C: Arm Label: Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine
D: Arm Label: Primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine, Drug: Chloroquine, Drug: Artemether Lumefantrine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Chloroquine, Drug: Artemether Lumefantrine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Placebo, Primaquine | Intervention Type: DRUG; Name: Artemether Lumefantrine; Assigned to Arm(s): Placebo, Primaquine

Answer: D